Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation

Alnylam Pharmaceuticals (ALNY) closed on August 12, 2025, with a 1.17% decline, while its trading volume surged 49.94% to $0.65 billion, ranking 168th in market activity. The stock is under pressure as the company prepares for a key data presentation at the European Society of Cardiology (ESC) Congress 2025, where results from its hypertension drug zilebesiran and ATTR amyloidosis therapy vutrisiran will be highlighted.

The company announced it will present late-breaking data from the KARDIA-3 Phase 2 trial of zilebesiran, an RNAi therapeutic targeting hypertension, at the ESC Congress on August 30. The study evaluates the drug’s potential to reduce cardiovascular risk by inhibiting angiotensinogen. Additionally, Alnylam will share 12-month follow-up results from the HELIOS-B trial of vutrisiran in ATTR-CM patients, reinforcing its position in rare disease therapies. These updates aim to demonstrate the long-term efficacy of its flagship products.

Alnylam’s recent presentation at the Canaccord Genuity Growth Conference emphasized its robust pipeline and financial stability, with management reiterating the “P5x25” strategy to deliver transformative medicines by 2025. The company’s quarterly subcutaneous therapies, including vutrisiran and patisiran, remain central to its growth narrative. However, investors are cautious about regulatory uncertainties for zilebesiran, as its safety and efficacy have yet to be validated by health authorities.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a total profit of $2,340 from 2022 to the present. However, the approach faced a maximum drawdown of -15.3% on October 27, 2022, underscoring the volatility inherent in volume-driven trading strategies.